Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2006; 12(17): 2756-2761
Published online May 7, 2006. doi: 10.3748/wjg.v12.i17.2756
Published online May 7, 2006. doi: 10.3748/wjg.v12.i17.2756
Table 1 Demographic characteristics of the enrolled patients
| Group | Ecabet group | Cimetidine group | P |
| (n = 133) | (n = 139) | ||
| Gender (male:female) | 47:86 | 47:92 | NS |
| Age (yr) | 45.0 ± 12.9 | 47.5 ± 12.5 | NS |
| Weight (kg) | 59.6 ± 10.0 | 58.5 ± 9.0 | NS |
| Height (cm) | 162.7 ± 8.0 | 161.8 ± 7.7 | NS |
| Smoking (%) | 23 (17.3) | 16 (11.5) | NS |
| Alcohol intake (%) | 47 (35.3) | 38 (27.3) | NS |
- Citation: Lee JH, Kim JJ, Hahm KB, Lee DH, Kim N, Kim SK, Park JJ, Choi SR, Lee JH, Lee ST, Lee EH, Rhee JC. Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial. World J Gastroenterol 2006; 12(17): 2756-2761
- URL: https://www.wjgnet.com/1007-9327/full/v12/i17/2756.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i17.2756